Weight & metabolic
Cagrilintide
AM833
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It is the amylin component of CagriSema and is also under investigation as a single agent for weight management. It is not approved as a standalone product.
Also known as: AM 833
- Status
- Cagrilintide is in Phase 3 clinical trials and not approved.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- Approximately 7 to 8 days, consistent with once-weekly dosing.
- How it's taken
- Once-weekly subcutaneous injection (investigational)
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- Amylin
How Cagrilintide works
Cagrilintide is a modified, acylated analogue of human amylin, a hormone co-secreted with insulin by pancreatic beta cells. It acts at amylin and calcitonin receptors in the area postrema and hypothalamus to slow gastric emptying, suppress post-meal glucagon secretion and increase satiety. The mechanism is distinct from and complementary to GLP-1 agonism, which is the rationale for combining the two.
What research has looked at
- Phase 2 data supported dose-dependent weight reduction as monotherapy.
- Because the amylin pathway is separate from the incretin pathway, combination with semaglutide produced greater weight reduction than either component alone in the CagriSema programme.
- Acylation extends the half-life sufficiently for once-weekly dosing, unlike pramlintide which requires dosing with each major meal.
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Gastrointestinal effects including nausea, vomiting and constipation, consistent with delayed gastric emptying.
- Injection-site reactions.
- As an investigational agent, its long-term safety profile is not established, and no regulator has approved it as a single agent.
- Material sold outside a clinical trial is not a regulated pharmaceutical product and its identity, purity and dose accuracy are unverified.
Sources
- PubMed research on cagrilintide amylin analogue CagriSema · NIH · National Library of Medicine
- DrugBank record for cagrilintide · DrugBank
- Active clinical trials for cagrilintide · U.S. National Library of Medicine
Track Cagrilintide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Cagrilintide FAQ
What is Cagrilintide?
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It is the amylin component of CagriSema and is also under investigation as a single agent for weight management. It is not approved as a standalone product.
How does Cagrilintide work?
Cagrilintide is a modified, acylated analogue of human amylin, a hormone co-secreted with insulin by pancreatic beta cells. It acts at amylin and calcitonin receptors in the area postrema and hypothalamus to slow gastric emptying, suppress post-meal glucagon secretion and increase satiety. The mechanism is distinct from and complementary to GLP-1 agonism, which is the rationale for combining the two.
Is Cagrilintide FDA approved?
No. Cagrilintide is in Phase 3 clinical trials and not approved. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Cagrilintide?
Reported half-life: Approximately 7 to 8 days, consistent with once-weekly dosing.
How is Cagrilintide taken?
Once-weekly subcutaneous injection (investigational).
What side effects have been reported with Cagrilintide?
Reported in the sources: Gastrointestinal effects including nausea, vomiting and constipation, consistent with delayed gastric emptying; Injection-site reactions; As an investigational agent, its long-term safety profile is not established, and no regulator has approved it as a single agent; Material sold outside a clinical trial is not a regulated pharmaceutical product and its identity, purity and dose accuracy are unverified.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.